Leiomyosarcoma of the renal vein: analysis of outcome and prognostic factors in the world case series of 67 patients
, , , , und | 23. Dez. 2016
Über diesen Artikel
Article Category: Research Article
Online veröffentlicht: 23. Dez. 2016
Seitenbereich: 56 - 64
Eingereicht: 11. Juni 2016
Akzeptiert: 05. Okt. 2016
DOI: https://doi.org/10.1515/raon-2016-0051
Schlüsselwörter
© 2017 Marko Novak, Andraz Perhavec, Katherine E. Maturen, Snezana Pavlovic Djokic, Simona Jereb, Darja Erzen
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Univariate analysis of overall, local recurrence free and distant metastases free survival (log-rank)
| Characteristic | Subgroup | OVERALL SURVIVAL | LOCAL RECURRENCE FREE SURVIVAL | ||||
|---|---|---|---|---|---|---|---|
| Alive (n = 39) | Dead (n = 17) | p-value | No LR (n = 45) | LR (n = 11) | p-value | ||
| Age | ≤ 50 | 13 | 5 | 0.285 | 15 | 3 | 0.519 |
| 50 | 26 | 12 | 30 | 8 | |||
| Gender | F | 32 | 15 | 0.812 | 38 | 9 | 0.993 |
| M | 7 | 2 | 7 | 2 | |||
| Side | L | 29 | 9 | 0.448 | 31 | 7 | 0.987 |
| R | 10 | 8 | 14 | 4 | |||
| Weight loss | Y | 5 | 6 | 0.414 | 9 | 2 | 0.734 |
| N | 34 | 11 | 36 | 9 | |||
| Palpable mass | Y | 9 | 6 | 0.581 | 12 | 4 | 0.562 |
| N | 30 | 11 | 34 | 9 | |||
| Operation | Nephrectomy | 35 | 15 | 0.543 | 41 | 9 | 0.562 |
| Tumorectomy | 2 | 2 | (nephrectomy or tumorectomy vs. compartment) | 2 | 2 | ||
| Compartment | 2 | 0 | 2 | 0 | |||
| Intracaval luminal extension | Y | 5 | 3 | 0.340 | 4 | 4 | 0.016 |
| N | 34 | 14 | 41 | 7 | |||
| Tumour size | ≤ 10 cm | 23 | 10 | 0.485 | 28 | 5 | 0.219 |
| > 10 cm | 11 | 3 | (≤ 10 cm vs. > 10 cm) | 11 | 3 | (≤ 10 cm vs. > 10 cm) | |
| Unknown | 5 | 4 | 6 | 3 | |||
| Grade | 1 | 4 | 2 | 0.265 (1 vs. 2 or 3) | 6 | 0 | 0.05 (1 vs 2 or 3) |
| 2 or 3 | 13 | 6 | 12 | 7 | |||
| Unknown | 22 | 9 | 27 | 4 | |||
| Margins | Negative | 14 | 1 | 0.014 (neg. vs. pos.) | 12 | 3 | 0.096 (neg. vs. pos.) |
| Positive | 1 | 1 | 0 | 2 | |||
| Unknown | 24 | 15 | 33 | 6 | |||
| Mitoses/10hpf | <10 | 8 | 2 | 0.782 (<10 vs. ≥10) | 8 | 2 | 0.244 (<10 vs. ≥10) |
| ≥10 | 2 | 1 | 1 | 2 | |||
| Unknown | 29 | 14 | 36 | 7 | |||
| Neoadjuvant/adjuvant chemotherapy | Y | 8 | 3 | 0.987 | 7 | 4 | 0.337 |
| N | 31 | 14 | 38 | 7 | |||
| Neoadjuvant/adjuvant raditherapy | Y | 6 | 4 | 0.165 | 8 | 2 | 0.975 |
| N | 33 | 13 | 37 | 9 | |||
Patients data and histologic variables, treatment modalities and disease progression
| Characteristic | Subgroup | Value (n = 67) | % |
|---|---|---|---|
| Age at diagnosis (year) | Mean | 56.6 | |
| Range | 27–93 | ||
| Gender | Female | 51 | 76.1 |
| Male | 16 | 23.9 | |
| Side | Left | 46 | 68.7 |
| Right | 21 | 31.3 | |
| Size (cm) | Mean | 8.9 | |
| Range | 3.5–25 | ||
| Tumour thrombus extension | IVC | 9 | 13.4 |
| Preoperative biopsy | Histology | 9 | 13.4 |
| Fine needle aspiration | 2 | 3.0 | |
| No biopsy | 56 | 83.6 | |
| Tumour grade | G1 | 6 | 9.0 |
| G2 | 8 | 11.9 | |
| G3 | 14 | 20.9 | |
| Unknown | 39 | 58.2 | |
| Surgical margins | Negative | 15 | 22.4 |
| Positive | 3 | 4.5 | |
| Unknown | 49 | 73.1 | |
| Operation | Nephrectomy | 60 | 89.6 |
| Tumorectomy | 4 | 6.0 | |
| Compartment resection | 2 | 3.0 | |
| No operation | 1 | 1.5 | |
| Preoperative treatment | Embolization | 3 | 4.5 |
| ChT | 1 | 1.5 | |
| RT + ChT | 2 | 3.0 | |
| Intraoperative treatment | RT | 1 | 1.5 |
| Postoperative treatment | RT | 7 | 10.4 |
| ChT | 9 | 13.4 | |
| ChT + RT | 1 | 1.5 | |
| Immunotherapy | 1 | 1.5 | |
| Disease progression | LR | 3 | 4.5 |
| M | 20 | 29.9 | |
| LR + M | 10 | 14.9 | |
| Total | 33 | 49.3 | |
| Site of dissemination | Liver | 17 | 25.4 |
| Lungs | 16 | 23.9 | |
| Bone | 8 | 11.9 | |
| Soft tissue | 4 | 6.0 |
j.raon-2016-0051.tab.003.w2aab3b8c70b1b7b1ab1b4b5Aa
| Characteristic | Subgroup | DISTAN1 METASTASES FREE SURVIVAL | ||
|---|---|---|---|---|
| No DM (n = 31) | DM (n = 25) | p-value | ||
| Age | ≤ 50 | 9 | 9 | 0.805 |
| > 50 | 22 | 16 | ||
| Gender | F | 27 | 20 | 0.221 |
| M | 4 | 5 | ||
| Side | L | 19 | 19 | 0.138 |
| R | 12 | 6 | ||
| Weight loss | Y | 2 | 9 | 0.087 |
| N | 29 | 16 | ||
| Palpable mass | Y | 5 | 10 | 0.277 |
| N | 26 | 15 | ||
| Operation | Nephrectomy | 27 | 23 | 0.336 |
| Tumorectomy | 3 | 1 | (nephrectomy or tumorectomy vs. compartment) | |
| Compartment | 1 | 1 | ||
| Intracaval luminal extension | Y | 4 | 4 | 0.284 |
| N | 27 | 21 | ||
| Tumour size | ≤ 10 cm | 21 | 12 | 0.210 |
| > 10 cm | 7 | 7 | (≤ 10 cm vs. > 10 cm) | |
| Unknown | 3 | 6 | ||
| Grade | 1 | 4 | 2 | 0.131 (1 vs. 2 or 3) |
| 2 or 3 | 9 | 10 | ||
| Unknown | 18 | 13 | ||
| Margins | Negative | 10 | 5 | 0.815 (neg. vs. pos.) |
| Positive | 1 | 1 | ||
| Unknown | 20 | 19 | ||
| Mitoses/10hpf | <10 | 9 | 1 | 0.266 (<10 vs. ≥10) |
| ≥10 | 1 | 2 | ||
| Unknown | 21 | 22 | ||
| Neoadjuvant/adjuvant chemotherapy | Y | 5 | 6 | 0.683 |
| N | 26 | 19 | ||
| Neoadjuvant/adjuvant radiotherapy | Y | 5 | 5 | 0.087 |
| N | 26 | 20 | ||